MicroApproach Raises ￥10 million in Extended Series B Round

(VCBeat) Feb. 8, 2021 -- Recently, Shenzhen MicroApproach Medical Technology Co., Ltd. ("MicroApproach") announced that it has extended the Series B investment round by an additional 10 million RMB. The round's extension was exclusively led by led by Neovision Capital. According to MicroApproach, the funds are earmarked for the expansion of its R&D center in Japan, recruitment of R&D staff, and the rapid launch of neurointerventional devices.

Prior to this, MicroApproach has received investment from Fortune Venture Capital, Sunz Fund, Ruifeng Kangqi and others.

MicroApproach was founded in 2015, focusing on the R&D, production and sales of emerging interventional medical products. Starting from interventional access products, MicroApproach has formed a series of product lines, such as hydrophilic coated guidewires, micro guidewires, micro catheters, suction catheters, covering coronary artery disease, peripheral vascular disease, neurointervention, and other fields.

In the opinion of Fu Xuesen, Chairman of MicroApproach, the company is favored by well-known investors because of its excellent R&D team, innovative technologies and products.

In terms of team, MicroApproach has recruited a group of senior R&D engineers from China and Japan who have more than 10 years of experience in the development of interventional products.

As for technologies, MicroApproach has set up R&D centers in China and Japan respectively. After years of cooperation between Chinese and Japanese teams, a number of breakthrough technologies have been developed. In addition, MicroApproach is one of the few innovative firms in China that can independently develop and produce their own products.

Besides, MicroApproach has completed the R&D and mass production of Trexcel™ neural micro guidewire, DrianPro™ peripheral micro guidewire, Rapidgo™ PTCA guidewire, Limcess™ controlled guidewire and others. At the same time, it has also completed the R&D and mass production of Wisucker™ suction catheter and RapidThrough™ microcatheter. At present, MicroApproach has set a comprehensive product portfolio.

Neovision Capital was founded in 2015. Key founders are from Costone Capital, J.P. Morgan and so on. Leveraging its core team's rich China-operational experiences, international resources and business acumen, Neovision Capital is actually dedicated to both early and growth-stage investment in healthcare and TMT sector in China. In order to leverage its core assets, the company actively contribute expertise in essential services including branding, marketing, channel development, overseas expansion, human resources and finance.